Views & Analysis Precision medicine and data science: the ‘new normal’ for dr... Balancing innovation and huge unmet patient need with burgeoning cost constraints.
News Lilly/Boehringer diabetes combos get cardio data boost Lilly/Boehringer gain further advantage in US diabetes market.
News Lilly and Boehringer biosimilar undercuts Lantus by 15% Sanofi under pressure following long-awaited biosimilar launch.
News Five UK pharma companies "named and shamed" by watchdog Companies' actions discredited the industry, says PMCPA.
News Lilly/Boehringer's long-acting diabetes pill approved in US Long-release pill is eighth drug to come from diabetes partnership.
News Diabetes drug Jardiance gains landmark cardiovascular approv... Lilly and Boehringer Ingelheim will now be able to promote their drug Jardiance in the US as a way for diabetes patients to reduce their risk of having a heart attack or stroke.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
